Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 60 or older who have a type of blood cancer called pre-B ALL (a form of acute lymphoblastic leukaemia) that has not been treated before, including both Philadelphia chromosome-positive and Philadelphia chromosome-negative types. A small amount of prior treatment (less than one week of certain medications, or a single dose of certain chemotherapy drugs) is still allowed.
- Adults aged 18 to 59 who have the same type of untreated pre-B ALL but who are considered too unwell for standard intensive treatment, and who have at least one significant health condition such as: poor general functioning, serious heart problems, serious lung problems, reduced kidney function, or significant liver problems. (Confirm specific definitions with the trial site.)
- Adults aged 60 or older who are considered unfit for intensive chemotherapy and have one or more other health conditions such as kidney disease, heart disease, uncontrolled high blood pressure, diabetes, or breathing problems, and whose general health functioning is rated at a certain level. (Confirm with trial site.)
- People whose general health and functioning falls within an acceptable range on a standard medical scale (rated 0–3 out of 5). (Confirm with trial site.)
- People with liver and kidney function within certain acceptable ranges, as measured by blood tests. (Confirm specific values with the trial site.)
- People who are willing and able to provide written consent to participate.
- People whose ALL is currently in first remission (meaning the cancer has responded to initial treatment).
- People of any age with ALL that has come back or not responded to treatment, or with certain related types of aggressive blood cancers involving the bone marrow.
- Jehovah's Witnesses of any age may be eligible.
Who may not be able to join:
- People who have a newly diagnosed type of blood cancer called Burkitt's Leukaemia or Burkitt's Lymphoma, T-cell ALL, or lymphoblastic lymphoma.
- People with serious active heart disease at a severe level as assessed by a doctor.
- People whose heart pumping function (ejection fraction) is measured at below 40%.
- People with active hepatitis (liver infection or inflammation).
- People who are pregnant or breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Elias Jabbour, MD, M.D. Anderson Cancer Center
Phone: 713-792-7026
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Maximum tolerated dose of inotuzumab ozogamicin based on incidence of dose limiting toxicities (Phase I); Progression free survival (PFS) in frontline elderly acute lymphoblastic leukemia (ALL) (Phase II); Response rate in refractory-relapsed acute lymphoblastic leukemia (ALL) (Phase II); Survival in refractory-relapsed acute lymphoblastic leukemia (ALL) (Phase II)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.